Euthymics Bioscience Obtains $3,000,000 New Round

  • Feed Type
  • Date
    11/28/2012
  • Company Name
    Euthymics Bioscience
  • Mailing Address
    43 Thorndike St. Cambridge, MA 02141
  • Company Description
    Euthymics Bioscience, Inc. is a neuroscience-focused clinical-stage company developing next-generation treatments for depression. Euthymics’ initial focus is on patients who do not respond adequately to SSRIs. EB-1010 for depression is expected to improve efficacy and reduce the leading side effects associated with poor adherence to standard antidepressants including weight gain, sexual dysfunction and cognitive impairment.
  • Website
    http://www.Euthymics.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $3,000,000
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed

By posting a comment, you agree to our terms and conditions.